JAK2 and essential thrombocythemia: Genomic analysis revealed the occurrence of a somatic activating point mutation in the JAK2-kinase at amino acid position 617 (JAK2-V617F) in the majority (95%) of PV patients and in approximately 50% of ET and PMF patients [4,5].